InnoCare Pharma (SHA:688428) received approval from China's Center for Drug Evaluation (CDE) to conduct a Phase III trial of its BCL2 inhibitor, ICP-248 (Mesutoclax), in combination with BTK inhibitor orelabrutinib for first-line treatment of CLL/SLL, according to a Tuesday filing with the Shanghai bourse.
The therapy aims to enhance remission and reduce resistance mutations. Previous Phase II results showed promising efficacy and safety.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。